metaEvidence - overview

button bars forest bayes pooled summary circles

benefit
(statisticaly significant)

benefit (nominaly significant, not statitically demonstrated)

not significant

harm statitically significant

harm not significant

low certainty due to bias


			deaths (OS)
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus pembrolizumab plus placebo
	pembrolizumab plus ipilimumab vs. pembrolizumab plus placebo	1
versus pemetrexed plus platin
	nivolumab plus ipilimumab vs. pemetrexed plus platin	1
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	3
	cemiplimab vs. Standard of Care (SoC)	1
	durvalumab alone vs. Standard of Care (SoC)	1
	durvalumab plus tremelimumab vs. Standard of Care (SoC)	1
	nivolumab alone vs. Standard of Care (SoC)	2
	pembrolizumab alone vs. Standard of Care (SoC)	4